Drug Profile
Pentetreotide - Pharm-Sintez
Alternative Names: Octreotide, 111In; Oktreotid, 111InLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Pharm-Sintez
- Class Cyclic peptides; Radiopharmaceutical diagnostics; Somatostatins
- Mechanism of Action Single-photon emission-computed tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Breast cancer; CNS cancer; Neuroendocrine tumours; Small cell lung cancer